Japan drug price reforms risk hurting investment: Bristol-Myers CEO
The Japanese government made reforms in 2018 that change how its national health system pays for new and innovative drugs
Author
FDA says new test finds “unacceptable levels” of impurity in heartburn drugs
However, the agency said its testing method found much lower levels of the impurity, N-nitrosodimethylamine (NDMA), than a higher…
Roche bid to recycle Gayzva for lupus nephritis wins FDA breakthrough tag
There are no FDA-approved medicines for lupus nephritis, a life-threatening symptom of the autoimmune disease lupus in which the…
Drugmakers file second court challenge to Canada’s new drug price rules
Canada published the final regulations in August, despite heavy lobbying from drug companies, which stand to lose revenue as…
Polyphor reinvents itself after abandoning antibiotic trial
Polyphor's prospects and its share price plunged this year when it halted a trial of its intravenous murepavadin antibiotic…
Bayer hires former Johnson & Johnson executive for pharma deals
Former J&J executive Marianne De Backer will take the role of Head of Business Development and Licensing at Bayer’s…
China expands drug bulk-buy programme, puts pressure on pharma firms
The programme, rolled out last year, saw 11 Chinese cities, including Beijing and Shanghai, band together behind a tender process…
Novartis’s Sandoz licenses proposed multiple sclerosis biosimilar
The medicine is in Phase III clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS)
AstraZeneca lupus drug shows promise after set-back last year
The drug had failed to meet its main goal in the final stage of one of the two clinical trials under the TULIP programme last year…
Purdue Pharma in discussion on $10 billion-$12 billion offer to settle opioid lawsuits: sources
Purdue is among several drugmakers and distributors that have been sued for fueling an opioid addiction crisis in the United…